Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series

Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.

Detalles Bibliográficos
Autores principales: Vitkauskaitė, Monika, Vinikovas, Artūras, Miglinas, Marius, Rimševičius, Laurynas, Čerkauskaitė, Agnė, Mačionienė, Ernesta, Ašakienė, Eglė
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922540/
https://www.ncbi.nlm.nih.gov/pubmed/35317070
http://dx.doi.org/10.1002/ccr3.5573
_version_ 1784669536053624832
author Vitkauskaitė, Monika
Vinikovas, Artūras
Miglinas, Marius
Rimševičius, Laurynas
Čerkauskaitė, Agnė
Mačionienė, Ernesta
Ašakienė, Eglė
author_facet Vitkauskaitė, Monika
Vinikovas, Artūras
Miglinas, Marius
Rimševičius, Laurynas
Čerkauskaitė, Agnė
Mačionienė, Ernesta
Ašakienė, Eglė
author_sort Vitkauskaitė, Monika
collection PubMed
description Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.
format Online
Article
Text
id pubmed-8922540
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89225402022-03-21 Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series Vitkauskaitė, Monika Vinikovas, Artūras Miglinas, Marius Rimševičius, Laurynas Čerkauskaitė, Agnė Mačionienė, Ernesta Ašakienė, Eglė Clin Case Rep Case Reports Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines. John Wiley and Sons Inc. 2022-03-15 /pmc/articles/PMC8922540/ /pubmed/35317070 http://dx.doi.org/10.1002/ccr3.5573 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Vitkauskaitė, Monika
Vinikovas, Artūras
Miglinas, Marius
Rimševičius, Laurynas
Čerkauskaitė, Agnė
Mačionienė, Ernesta
Ašakienė, Eglė
Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series
title Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series
title_full Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series
title_fullStr Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series
title_full_unstemmed Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series
title_short Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series
title_sort complement inhibitor eculizumab in thrombotic microangiopathy: single‐center case series
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922540/
https://www.ncbi.nlm.nih.gov/pubmed/35317070
http://dx.doi.org/10.1002/ccr3.5573
work_keys_str_mv AT vitkauskaitemonika complementinhibitoreculizumabinthromboticmicroangiopathysinglecentercaseseries
AT vinikovasarturas complementinhibitoreculizumabinthromboticmicroangiopathysinglecentercaseseries
AT miglinasmarius complementinhibitoreculizumabinthromboticmicroangiopathysinglecentercaseseries
AT rimseviciuslaurynas complementinhibitoreculizumabinthromboticmicroangiopathysinglecentercaseseries
AT cerkauskaiteagne complementinhibitoreculizumabinthromboticmicroangiopathysinglecentercaseseries
AT macionieneernesta complementinhibitoreculizumabinthromboticmicroangiopathysinglecentercaseseries
AT asakieneegle complementinhibitoreculizumabinthromboticmicroangiopathysinglecentercaseseries

Ejemplares similares